Quectel response to FCC about IoT module security
7.9.2023 16:03:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today commented on the recent letter and response being published by the FCC and the Select Committee of the US Congress questioning if Quectel’s IoT modules represent a potential security risk.
“We welcome the opportunity to work with the FCC and other U.S. government entities to demonstrate our compliance and best practice device security approach, says Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “We are committed to contributing to the advancement of a smarter world by delivering best-in-class and secure products. This commitment is evidenced by our extensive device OEM customer base and our constant focus on providing our customers with the best and most secure modules in the industry.”
The Select Committee to the US Congress’ letter to the FCC had several misconceptions about how Quectel modules work. Quectel’s clarification regarding the statements made in the letter is as follows.
Committee letter: “Connectivity modules are typically controlled remotely and are the necessary link between the device and the internet.”
Quectel’s U.S. customers or their customers’ third-party suppliers/service providers handle device and data management exclusively. Firmware updates are managed and controlled by the device original equipment manufacturer (OEM), not Quectel.
Committee letter: “Serving as the link between the device and the internet, these modules have the capacity both to brick the device and to access the data flowing from the device to the web server that runs each device”
The control of Quectel modules resides with the microcontroller unit (MCU) or central processing unit (CPU) embedded within the customer's device. Quectel itself does not possess any control; instead, this authority rests solely with the OEM – the entity responsible for developing the device. Remote management of the device is achievable solely through the OEM's device management platform. A notable instance of this, referred to in the letter, is the widely covered case involving John Deere agricultural equipment, where just the OEM typically can disable the equipment by accessing and shutting down its own MCU’s controlling the machine.
Committee letter: “As a result, if the CCP can control the module, it may be able to effectively exfiltrate data or shut down the IoT device.”
Once Quectel modules leave the factory and are delivered to its customers, Quectel customers own the data, and Quectel has no access to any of the data collected. The ownership, control, storage, and modification of the data generated by IoT devices within the market firmly rest with the OEM device makers and its customers. Even in the rare cases outside of the U.S. where Quectel resells the connectivity service of a wireless carrier, Quectel does not have access to the device data.
Committee letter: “This raises particularly grave concerns in the context of critical infrastructure and any type of sensitive data.”
Applications that require high security, such as critical infrastructure, typically use private access point names (APNs) and other methods which strictly control and monitor network access. This can be used to control and monitor any data flowing to and from the device. Critical infrastructure is meticulously fashioned with a multi-tiered security approach defined and implemented solely by the device OEM, not Quectel.
The cellular industry is heavily regulated and requires intensive testing and accreditation. Carrier and regulatory certifications are executed by trusted third-party labs and carrier labs, assuring that the module complies with strict technical requirements. The Quectel modules have obtained certifications from the FCC, PCS Type Certification Review Board (PTCRB) and major carriers throughout the world, which underlines Quectel’s commitment to meeting rigorous industry standards.
In addition to cellular modules, Quectel also provides Wi-Fi, Bluetooth and GNSS modules and antennas. As a GSMA member, Quectel and its carrier partners comply with all cellular industry regulations and applicable standards to ensure that end customer data is securely transmitted between customer device and mobile network operator. Quectel does not have access to ANY of the device data.
Quectel is committed to delivering high-quality, best-in-class, secure modules and go above and beyond industry standard practices by conducting independent third-party cyber security audits. More recently Quectel also retained the security firm Finite State, which is auditing and penetration testing the security of its modules through rigorous security testing, improved software supply chain visibility, and comprehensive software risk management. Quectel is also participating in the formulation of new industry security certification standards, such as the CTIA Cybersecurity Certification Working Group and pursuing additional cyber security certifications from various U.S. entities as new standards are formulated and adopted.
Qualcomm manufactures the chipsets and software platforms that are at the core of the Quectel modules. “Our Qualcomm partnership underlines the importance we place on working with well-trusted and secure partners from across the ecosystem to deliver high-quality solutions globally,” Mr. Muhrer continues. “Quectel's impact on the global IoT industry is profound. We supplied millions of cellular modules to support the distribution of Covid-19 vaccines for leading U.S. and global organizations including Pfizer, Johnson & Johnson, and other leading suppliers of vaccines. This underscores our commitment to playing a pivotal role in critical global initiatives.”
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X (formerly known as Twitter).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907525548/en/
Contact information
Media contact: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
